Real-world patterns on tumor mutation burden testing in a pan-tumor population
| Autor: | Sumesh Kachroo, Anirban Basu, Maxine D Fisher, Santosh Gautam, Richard W DeClue |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine Cancer Research medicine.medical_specialty Time Factors Clinical Decision-Making DNA Mutational Analysis Population 03 medical and health sciences 0302 clinical medicine Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols Exome Sequencing Biomarkers Tumor Humans Medicine Genetic Testing Practice Patterns Physicians' Precision Medicine education Aged Retrospective Studies education.field_of_study business.industry High-Throughput Nucleotide Sequencing Mean age General Medicine Middle Aged Survival Analysis Treatment Outcome 030104 developmental biology Oncology Anticancer treatment 030220 oncology & carcinogenesis Mutation Mutation (genetic algorithm) Cohort Female Observational study business Real world data |
| Zdroj: | Future Oncology. 17:1879-1887 |
| ISSN: | 1744-8301 1479-6694 |
| DOI: | 10.2217/fon-2020-1005 |
| Popis: | Background: There is limited real-world information on use of tumor mutational burden (TMB) testing and characteristics of patients receiving it. Materials & methods: Patients ≥18 years old and diagnosed with advanced solid tumors between 1 January 2015 and 31 January 2019 with TMB testing (TMB cohort) and without it (non-TMB) were included in this retrospective, observational study. Results: The TMB cohort (n = 202) was younger than non-TMB (n = 212) (mean age: 62.1 vs 65.6 at diagnosis; p = 0.005). There were more Black patients in the TMB cohort (21.3 vs 11.8% in non-TMB; p = 0.004). Clinical characteristics were comparable between the two cohorts; however, systemic anticancer treatment was higher among TMB cohort (91.6 vs 77.8% in non-TMB). Conclusion: Notable differences were observed between patients receiving TMB test and those not receiving it. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|